Advertisement
Research ArticleArticle

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit and Caly Chien
Drug Metabolism and Disposition October 2016, 44 (10) 1682-1691; DOI: https://doi.org/10.1124/dmd.116.070672

Abstract

Abiraterone acetate, the prodrug of the cytochrome P450 C17 inhibitor abiraterone, plus prednisone is approved for treatment of metastatic castration-resistant prostate cancer. We explored whether abiraterone interacts with drugs metabolized by CYP2C8, an enzyme responsible for the metabolism of many drugs. Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3–3.0 µM, 1.6–2.9 µM, 0.044–0.15 µM, and 5.4–5.9 µM, respectively). CYP2C8 inhibition was reversible and time-independent. To explore the clinical relevance of the in vitro data, an open-label, single-center study was conducted comprising 16 healthy male subjects who received a single 15-mg dose of the CYP2C8 substrate pioglitazone on day 1 and again 1 hour after the administration of abiraterone acetate 1000 mg on day 8. Plasma concentrations of pioglitazone, its active M-III (keto derivative) and M-IV (hydroxyl derivative) metabolites, and abiraterone were determined for up to 72 hours after each dose. Abiraterone acetate increased exposure to pioglitazone; the geometric mean ratio (day 8/day 1) was 125 [90% confidence interval (CI), 99.9–156] for Cmax and 146 (90% CI, 126–171) for AUClast. Exposure to M-III and M-IV was reduced by 10% to 13%. Plasma abiraterone concentrations were consistent with previous studies. These results show that abiraterone only weakly inhibits CYP2C8 in vivo.

Introduction

Abiraterone acetate in combination with prednisone is approved for the treatment of patients with metastatic castration-resistant prostate cancer in the pre- and postchemotherapy settings based on two pivotal phase 3 trials that demonstrated a significant survival benefit versus prednisone alone (de Bono et al., 2011; Fizazi et al., 2012; Rathkopf and Scher, 2013; Ryan et al., 2013, 2015). Abiraterone acetate is the prodrug of abiraterone, which selectively blocks the cytochrome P450 C17 (CYP17) complex that is required for androgen biosynthesis (Barrie et al., 1994; Potter et al., 1995). CYP17 is expressed in testicular, adrenal, and prostatic tumor tissues, and therefore abiraterone inhibits gonadal, extragonadal, and intratumoral androgen biosynthesis, resulting in profound reductions in circulating testosterone levels beyond those achieved by surgical or medical castration (Massard and Fizazi, 2011; Ryan and Tindall, 2011).

Cytochrome P450 enzymes play a central role in the metabolism of a wide range of drugs and chemical carcinogens (Guengerich 1988). CYP450 2C8 (CYP2C8), in particular, has emerged relatively recently as an important enzyme that is responsible for the metabolism of a diverse group of drugs in humans, including repaglinide, pioglitazone, rosiglitazone, paclitaxel, dasabuvir, and the androgen-signaling inhibitor enzalutamide (Daily and Aquilante, 2009; Gibbons et al., 2015). Available data suggest that genetic variation in CYP2C8 can alter drug disposition in vivo (Niemi et al., 2003, 2005; Kirchheiner et al., 2006). Given the role of CYP2C8 in drug metabolism, we designed a series of in vitro studies to evaluate the potential of abiraterone acetate and abiraterone and its major human metabolites (Supplemental Fig. 1) to inhibit CYP2C8. Repaglinide is a preferred substrate for CYP2C8 and is transported via organic anion transporting polypeptide (OATP1B1) in vivo (Kalliokoski et al., 2008); because this raises the possibility that OATP1B1 may influence drug metabolism by CYP2C8 in the in vitro and in vivo setting, we also assessed the effects of abiraterone and its metabolites on hepatic uptake of OATP1B1 substrates.

Based on the results of the in vitro investigations on CYP2C8 and OATP1B1, we conducted a clinical study to further evaluate the effect of abiraterone on CYP2C8 activity after a single dose of abiraterone acetate in healthy volunteers. Pioglitazone was selected as the CYP2C8 substrate probe because it undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups predominantly mediated via CYP2C8 (Jaakkola et al., 2006b), and its disposition is not affected by the polymorphism of the SLCO1B1 gene that encodes OATP1B1 (Kalliokoski et al., 2008). Two active pioglitazone metabolites, M-III and M-IV (Supplemental Fig. 2), which contribute to the long duration of glucose-lowering efficacy of pioglitazone (Eckland and Danhof, 2000), were also measured. Multiple cytochrome P-450 isoenzymes are involved in the metabolism of pioglitazone to M-IV, but the most important of these are CYP2C8/9 and, to a lesser extent, CYP3A4. M-IV can be further oxidized to form M-III (Eckland and Danhof 2000). Herein, we report the effects of abiraterone on CYP2C8 in in vitro and clinical studies.

Materials and Methods

Reagents and Supplies

For the in vitro CYP2C8 assays, abiraterone acetate (batch no. 35430017), abiraterone (batch no. 342293), and quercetin (batch no. 30466093) were used from internal stocks. For the OATP1B1 assays, abiraterone (PbOEL3a) was used from internal stocks. For both the CYP2C8 and OATP1B1 assays, abiraterone sulfate (batch no. 35616973) and abiraterone sulfate N-oxide (batch no. 39333595) were used from internal stocks. Rifampicin (batch no. EXTE_0201_210_1) and cyclosporin A (batch no. 39195100) were used from internal stocks. Amodiaquine, dimethylsulfoxide (DMSO), 3H-estradiol 17β-d-glucuronide (E2-17G), and 3H-repaglinide were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Gemfibrozil 1-O-β-glucuronide was purchased from Toronto Research Chemicals (Toronto, ON). The NADPH-regenerating system (NRS) was obtained from BD Biosciences (Woburn, MA). Cryopreserved human hepatocytes were obtained from CellzDirect Invitrogen (Thermo Fisher Scientific Inc., Grand Island, NY).

The BD Gentest was purchased from BD Biosciences. The Strata Impact protein precipitation 96-well plates were purchased from Phenomenex Corp. (Torrance, CA). Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was carried out on a Shimadzu binary 10AD-vp liquid chromatography pump system (Shimadzu Scientific Instruments, Columbia, MD) with Leap CTC PAL autosampler (Leap Technologies, Carrboro, NC) coupled to a Sciex API 4000 triple quadrupole mass spectrometer (Sciex, Foster City, CA). The swinging bucket centrifuge (Eppendorf 5417R) was obtained from Eppendorf Biotools (ON). The Xbridge C18 column was obtained from Waters Corporation (Milford, MA), and the API4000, with a Turbo-Ionspray interface, was obtained from Sciex (Concord, ON). The Luna Phenylhexyl column was purchased from Phenomenex Corp.

Evaluation of CYP2C8 Activity in Human Liver Microsomes

Human liver microsomes were pooled from 50 male and female donors, characterized by BD Gentest, and then stored at 20 mg/ml in 250 mM sucrose at −70°C until use. The microsomes were thawed and then diluted with incubation buffer (100 mM potassium phosphate, 5 mM magnesium chloride, 1 mM EDTA). Assays were conducted in triplicate under optimized conditions (i.e., protein and substrate concentrations and incubation time) in a total incubation volume of 160 µl. Stock solutions of abiraterone acetate, abiraterone, abiraterone sulfate, and abiraterone sulfate-N-oxide were prepared at 10 or 30 mM in DMSO, serially diluted in DMSO, and then added to the microsomal suspension to yield eight final concentrations ranging from 0 to 30 or 60 µM, depending on the test compound. Because of the substantial CYP2C8 inhibition observed with abiraterone sulfate up to 30 µM, the assay was repeated at lower inhibitor concentrations (up to 5 µM) to obtain a more accurate IC50 determination, defined as the inhibitor concentration producing a 50% reduction in maximal CYP2C8 enzyme activity. As a positive control, the CYP2C8 inhibitor quercetin was evaluated in triplicate at concentrations ranging from 0.03 to 30 µM. The probe substrate amodiaquine was added to the microsome suspension to yield a final concentration of 2 µM. The organic content in the final incubation mixture did not exceed 0.35%. For the time-dependent assay, gemfibrozil 1-O-β-glucuronide was evaluated as a time-dependent positive control.

After preincubation at 37°C for 10 minutes, the reactions to determine whether CYP2C8 activity was reversibly inhibited by abiraterone acetate, abiraterone, abiraterone sulfate, and abiraterone sulfate-N-oxide were initiated by the addition of an NRS (40 µl), yielding final concentrations of 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, and 0.4 U/ml glucose-6-phosphate dehydrogenase. After incubation for 15 minutes, the reactions were quenched by the addition of 160 µl of acetonitrile and then transferred to a 2-ml Strata Impact protein precipitation 96-well plate containing 300 μl of acetonitrile and 100 μl of N-desethylamodiaquine-d3 (1.5 µM) as internal standard. The samples were filtered, evaporated to dryness under nitrogen, and reconstituted in 250 μl of mobile phase (1:1 methanol:water containing 0.1% acetic acid). Time-dependent inhibition was assessed by incubating eight serially diluted concentrations (up to 15 µM) of the test compounds with and without NRS for 60 minutes and then transferring of an aliquot to a secondary incubation containing 10 µM amodiaquine (5 × Km) and NRS to assay residual CYP2C8 activity. After 15 minutes, samples were quenched and prepared as described for the reversible inhibition samples. Analysis by LC-MS/MS was carried out on a Shimadzu binary 10AD-vp liquid chromatography pump system with Leap CTC PAL autosampler coupled to a Sciex API 4000 triple quadrupole mass spectrometer. The possibility of ion suppression of the analyte resulting from coelution with the test compound was evaluated before injection of the incubated samples. The acquired data were processed using Analyst version 1.5.1 (AB Sciex, Concord, ON), and the area ratios of metabolite and internal standard peaks were exported to Excel (Microsoft, Redmond, WA) and SigmaPlot version 11 (Systat Software, Inc., San Jose, CA) for nonlinear regression analysis.

The inhibitory effect of test compounds on CYP2C8-mediated amodiaquine metabolism was evaluated by determining the rate of formation of N-desethylamodiaquine as a function of inhibitor concentration, normalized to the maximal activity in the absence of inhibitor (i.e., vehicle control). IC50 values for the inhibition of CYP2C8 enzyme activity were determined from semi-log plots of residual activity versus inhibitor concentration. In the time-dependent assay, separation between the plus and minus NADPH titration curves of percent residual CYP2C8 activity as a function of the molar ratio of inhibitor to CYP2C8 concentration would indicate the potential for time-dependent inhibition. In addition, the apparent partition ratio, representing the ratio of substrate molecules turned over per enzyme molecule inactivated, was determined from the extrapolated x-intercept of the initial linear portion of the titration curve.

Evaluation of OATP1B1 Activity in Hepatocytes

Cryopreserved human hepatocytes were thawed according to the manufacturer’s instructions. The hepatocytes were suspended at a concentration of 1 × 106 cells/ml in Krebs-Henseleit buffer containing Hepes 12.5 mM, pH 7.4, and preincubated on a shaker at 37°C for at least 5 minutes. Test compound (6, 20, and 40 µM abiraterone; or its metabolites 6, 20, and 40 µM abiraterone sulfate; or 6, 20, and 60 µM abiraterone sulfate-N-oxide), positive reference inhibitors (100 µM rifampicin or 10 µM cyclosporin A), or solvent (DMSO, negative control) was added; then, after an additional preincubation period, uptake was initiated by adding radiolabeled OATP1B1 substrate [E2-17G (final concentration 1 µM; 10 GBq/mmol) or 3H-repaglinide (final concentration 0.5 µM; 10 GBq/mmol)] to the hepatocyte suspension (final volume 2 ml). All incubations were stirred continuously.

Triplicate 200-µl samples were removed after 1 and 5 minutes and transferred to Eppendorf 1.5-ml microtubes prefilled with 400 µl of silicon/mineral oil (82:18, v/v) layered over 10% perchloric acid (250 µl) and immediately centrifuged (10,500 rpm) for 30 seconds in a swinging bucket centrifuge (Eppendorf 5417R). After centrifugation, the tubes were frozen on dry ice, the content cut at the oil interface, and both parts transferred into separate scintillation vials. To evaluate passive background uptake, negative control incubations were performed at 0–4°C, with triplicate samples removed after 1 and 5 minutes and processed as described previously. Protein concentrations in the incubation mixtures were quantified by bicinchoninic acid assay. The measured radioactivity was converted to picomoles uptake per 106 cells and per milligram of protein, and IC50 values were calculated as the concentration producing 50% inhibition of the initial linear uptake rate of the probe substrate.

After correction for background radioactivity, measured radioactivity was converted to picomoles uptake per 106 cells and per milligram of protein using Microsoft Excel. After plotting the percentage of residual hepatic uptake (compared with 100% residual activity in the solvent control) against the inhibitor concentration, IC50 values were calculated using a nonlinear regression program (Enzyme Kinetics 1.3 module of Sigmaplot 12.0, Systat Software, Inc.).

Clinical Study

Study Design and Population.

A single-center, open-label, two-period, sequential-design study was conducted in healthy male subjects. An independent ethics committee approved the study protocol before any study-related procedures were started. The study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in compliance with Good Clinical Practices and applicable regulatory requirements. Eligible subjects were men aged 18–55 years, with a body mass index of 18–30 kg/m2, body weight ≥50 kg, and normal cardiac function. Subjects with a history of or current clinically significant medical illness, abnormal liver or renal function, or history of drug or alcohol abuse within the past 3 years were excluded. All subjects provided written informed consent before enrollment.

Subjects were admitted to the study center on day –1. After an overnight fast of at least 10 hours, all subjects received pioglitazone 15 mg (1 × 15-mg tablet; TEVA, Castleford, UK) on day 1 and abiraterone acetate, 1000 mg (4 × 250-mg tablets; Janssen-Cilag, Beerse, Belgium) followed 1 hour later by pioglitazone on day 8. A one-sequence crossover design was applied to the study based on guidance from the US Food and Drug Administration (U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2012). Drug Interaction Studies - Study Design: Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.). This proposed study design allows for a clean measurement of the pharmacokinetics of pioglitazone and its metabolites at baseline (i.e., control) from all subjects before coadministration with abiraterone acetate and minimizes unexpected carryover effect in case a significant interaction occurs. Study drugs were swallowed whole with 240 ml of noncarbonated water. A standardized breakfast with medium fat content was provided on both days after the pioglitazone dose, but no other food was to be consumed for 4 hours. Throughout the study, prescription or nonprescription medications other than the study drugs were prohibited, except for acetaminophen.

Pharmacokinetics.

Serial blood samples were collected predose and up to 72 hours after each pioglitazone dose for determination of plasma concentrations of pioglitazone, M-III, and M-IV. Serial blood samples were also collected after administration of abiraterone acetate on day 8 for the determination of plasma abiraterone concentrations.

Plasma concentrations of abiraterone were determined using a validated method described previously (Marbury et al., 2014). In brief, a liquid-liquid extraction with t-butyl methyl ether followed by LC-MS/MS was carried out. All results were within the predefined acceptance criteria as described in guidance from the FDA (U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) (2001). Guidance for industry bioanalytical method validation. Food and Drug Administration. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.). The lower limit of quantification (LLOQ) was 0.2 ng/ml.

Pioglitazone plasma concentrations were determined using a validated method. Samples were subjected to protein precipitation with acetonitrile using a stable isotope-labeled internal standard. After centrifugation, the supernatant was injected into an LC-MS/MS system. A gradient of ammonium acetate (pH 2.5) with acetonitrile was run over an Xbridge C18 column. Detection was done with multiple reaction monitoring on an API4000, with a Turbo-Ionspray interface, operating in positive ion mode. The LLOQ was 0.5 ng/ml. All results were within the predefined acceptance criteria. Plasma concentrations of the M-III and M-IV metabolites of pioglitazone were determined using an LC-MS/MS assay. Samples were subjected to protein precipitation with acetonitrile using a stable isotope-labeled internal standard. After centrifugation, the supernatant was injected into an LC-MS/MS system. A gradient of ammonium formate (pH 2.5) with methanol was run over a Luna Phenylhexyl column. Detection was done with multiple reaction monitoring on an API4000, with a Turbo-Ionspray interface operating in positive ion mode. The LLOQ for both metabolites was 0.5 ng/ml. All results were within the predefined acceptance criteria.

Pharmacokinetic parameters for pioglitazone, M-III, M-IV, and abiraterone were determined from the individual plasma concentration data and actual sampling times using noncompartmental analysis with validated WinNonlin software, version 6.3 [Pharsight Corp., (Certara), Princeton, NJ]. The primary pharmacokinetic parameters of interest were the Cmax, the area under the plasma concentration–time curve from time zero to the last observed quantifiable concentration (AUClast), and the AUC from time zero to infinite time (AUC∞). AUClast was calculated by linear trapezoidal method. AUC∞ was calculated as the sum of AUClast and Clast/λz, where Clast was the last observed quantifiable concentration.

Safety.

Safety was monitored throughout the study and included adverse events, vital signs, clinical laboratory testing, 12-lead electrocardiograms, and physical examinations. Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Version 16.0, and their severity graded according to the National Cancer Institute—Common Terminology Criteria for Adverse Events version 4.0.

Statistics.

Using an intrasubject coefficient of variation of 22% for Cmax and 19% for AUC based on published data on pioglitazone (Karim et al., 2007), a sample size of 12 subjects was considered sufficient for point estimates of the geometric mean ratios (GMRs) of Cmax and AUC, with and without coadministration of abiraterone acetate, to fall within 85% and 117% and within 87% and 115% of their true values, respectively, with 90% confidence. A sample size of 16 subjects was planned, assuming a dropout rate of 25%.

Mean plasma concentration data and mean pharmacokinetic parameters were summarized descriptively. The statistical analysis included subjects who had pharmacokinetic parameter estimates for pioglitazone on both day 1 (pioglitazone alone) and day 8 (pioglitazone coadministered with abiraterone). The GMRs of the pharmacokinetic parameters (Cmax, AUClast, and AUC∞) of pioglitazone with and without coadministration of abiraterone acetate and the associated 90% confidence intervals were constructed using least squares means and intrasubject coefficients of variation from a mixed-effects model of log-transformed pharmacokinetic parameters. A similar statistical analysis was done on the pharmacokinetic parameters of M-III and M-IV. All safety parameters were summarized descriptively.

Results

Effect on CYP2C8 Activity in Human Liver Microsomes.

Abiraterone acetate, abiraterone, and the major human metabolites of abiraterone inhibited the CYP2C8-mediated metabolism of amodiaquine to N-desethylamodiaquine in human liver microsomes in a concentration-dependent manner (Fig. 1). The rank order of potency for inhibiting CYP2C8 was abiraterone sulfate > abiraterone acetate ≈ abiraterone > abiraterone sulfate-N-oxide (Table 1). Only abiraterone sulfate had submicromolar IC50 values for CYP2C8 inhibition (0.04 µM) using a concentration range of 0.005–5.0. In comparison, the respective IC50 value for abiraterone sulfate-N-oxide was 5.4 µM. The IC50 values for CYP2C8 inhibition for abiraterone acetate and abiraterone were 3.0 µM and 2.9 µM, respectively.

Fig. 1.
Fig. 1.

Concentration-response curves for CYP2C8 inhibition by abiraterone acetate, abiraterone, its metabolites, and the positive control, quercetin, in human liver microsomes. Shown are the results from assay 1 (A), assay 2 (B), assay 3 (C), and assay 4 (D). Each point is the mean of three replicate determinations. Outliers had poor solubility as evidenced by visible precipitation.

View this table:
TABLE 1

Effect of abiraterone acetate, abiraterone, and its metabolites on CYP2C8 activity in human liver microsomes

To determine whether CYP2C8 was inhibited in a time-dependent manner, the experiments were conducted in the presence and absence of an NRS during preincubation. Gemfibrozil 1-O-β-glucuronide was included as a time-dependent positive control inhibitor, and quercetin was included as a reversible negative control inhibitor. Gemfibrozil 1-O-β-glucuronide produced substantial inhibition of CYP2C8 activity in the presence of NADPH but minimal enzyme activity loss in the absence of NADPH; the apparent partition ratio (APR), which represents the ratio of substrate turnover per molecule of enzyme being inactivated, was 78, indicating strong and rapid time-dependent inhibition of CYP2C8. In cases of time-dependent inhibition, we defined APR values less than 100 as strong inhibition and values between 100 and 500 as moderate inhibition (Lim et al., 2005). Conversely, there was no NADPH-dependent loss of CYP2C8 activity with quercetin, abiraterone, abiraterone sulfate, or abiraterone sulfate N-oxide, indicating no time-dependent inhibition of CYP2C8 (Fig. 2), and therefore APR values were not determined. The effects on CYP2C8 activity observed in the presence and absence of NADPH by these compounds reflected reversible inhibition. Since incubation times were short (e.g., 8–12 minutes for amodiaquine) the inhibitor/metabolite was presumed stable except for any NADPH-dependent turnover.

Fig. 2.
Fig. 2.

Evaluation of time-dependent inhibition of CYP2C8 in human liver microsomes by incubation in the presence or absence of an NADPH-regenerating system.

Effect on OATP1B1 Activity in Human Hepatocytes.

Based on the CYP2C8 inhibition results in human liver microsomes, a clinical drug-drug interaction study was planned to further evaluate the relevance of the in vitro findings. According to the literature, repaglinide is the highly sensitive CYP2C8 probe substrate (VandenBrink et al., 2011); however, because repaglinide is transported via OATP1B1 (Kalliokoski et al., 2008), the effect of abiraterone and its metabolites on OATP1B1-mediated uptake of 3H-E2-17G and 3H-repaglinide was first investigated in vitro using human hepatocytes. Cell viability was 82% in the presence of 0.25% DMSO vehicle and was unaffected by the addition of the test compounds. Abiraterone and its metabolites inhibited uptake of 3H-E2-17G and 3H-repaglinide when measured after incubations of 1 and 5 minutes (Fig. 3). At the lowest concentration tested, abiraterone 6 µM inhibited 3H-E2-17G uptake by 68.6% and 3H-repaglinide uptake by 58.5% at 5 minutes. When corrected for the passive component of total uptake, the inhibition by abiraterone 6 µM was 78% and 96%, respectively. Comparable results were found with abiraterone sulfate and abiraterone sulfate N-oxide (Fig. 3). The positive controls, cyclosporin A and rifampicin, also efficiently inhibited 3H-E2-17G and 3H-repaglinide uptake. The underlying cause of the increased uptake of 3H-repaglinide in the presence of abiraterone sulfate N-oxide 6 µM is unknown (Fig. 3B).

Fig. 3.
Fig. 3.

Effect of abiraterone and its metabolites on OATP1B1-mediated uptake of 3H-E2-17G and 3H-repaglinide in human hepatocytes after 1 minute (A) and 5 minutes (B) of incubation.

Effect on CYP2C8 Activity in Healthy Volunteers.

Because abiraterone and its metabolites inhibited OATP1B1-mediated uptake of repaglinide in vitro, it was necessary to select another CYP2C8 probe substrate for the clinical drug-drug interaction study. Pioglitazone was selected for its sensitivity to CYP2C8 inhibition, its demonstrated safety and tolerability in healthy volunteers, and the short washout period needed between doses. Moreover, a 15-mg dose of pioglitazone provides sufficient plasma drug levels for bioanalytical quantification through 48 hours after dosing.

Sixteen healthy male subjects were enrolled. The study cohort had a median age of 46.5 years (range, 23–54 years), median weight of 81.3 kg (range, 60.6–101 kg), and median body mass index of 25.6 kg/m2 (range, 20.3–28.4 kg/m2); all were white. Fifteen subjects completed the study as planned; one subject was discontinued before administration of study drugs on day 8 due to a positive screen for codeine.

After oral administration of pioglitazone, mean plasma pioglitazone concentrations increased rapidly, with a median time to reach Cmax of 3.0 hours when given alone and 4.0 hours when given 1 hour after abiraterone acetate (Fig. 4A). Thereafter, plasma pioglitazone concentrations declined in an apparent first-order manner, with a mean elimination half-life of 9.3 hours when administered alone and 8.6 hours when coadministered with abiraterone acetate. In general, the shapes of the plasma concentration–time curves were similar after both pioglitazone doses, although mean plasma pioglitazone concentrations appeared to be slightly higher at all time points when pioglitazone was coadministered with abiraterone acetate. The pharmacokinetic parameters for pioglitazone are shown in Table 2. Most subjects had higher pioglitazone Cmax, AUClast, and AUC∞ values when pioglitazone was dosed 1 hour after abiraterone acetate compared with when pioglitazone was administered alone (Fig. 5). Based on the GMRs in the statistical analysis, the Cmax of pioglitazone increased by 25% and the AUClast and AUC∞ increased by approximately 46% when pioglitazone was coadministered with abiraterone acetate.

Fig. 4.
Fig. 4.

Log-linear mean plasma pioglitazone (A), M-III (B), and M-IV (C) concentration–time curves after a single 15-mg oral dose of pioglitazone administered alone or 1 hour after abiraterone acetate.

View this table:
TABLE 2

Pharmacokinetic parameters of pioglitazone and its M-III and M-IV metabolites after administration of pioglitazone 15 mg alone or 1 hour after abiraterone acetate (AA)

Fig. 5.
Fig. 5.

Individual and mean pharmacokinetic parameters for pioglitazone after a single 15-mg oral dose of pioglitazone administered alone or 1 hour after abiraterone acetate.

M-III and M-IV appeared slowly in plasma, reaching peak concentrations after a median of 12 hours when pioglitazone was administered alone and after a median of 24 hours when pioglitazone was administered after abiraterone acetate (Fig. 4, B and C). In general, the shapes of the M-III and M-IV concentration–time curves were similar after each pioglitazone dose, although mean plasma concentrations of both metabolites appeared to be slightly lower at all time points when pioglitazone was coadministered with abiraterone acetate. Based on the GMRs, the Cmax of M-III was reduced by 13% and the AUClast was reduced by 10% when pioglitazone was coadministered with abiraterone acetate; the AUC∞ was not affected by abiraterone acetate administration (Table 2). For M-IV, the Cmax was reduced by nearly 12%, the AUClast was reduced by 9.5%, and the AUC∞ was lowered by 8.5% when abiraterone acetate was administered before pioglitazone.

After administration of abiraterone acetate on day 8, mean plasma abiraterone concentrations increased rapidly, with a median tmax of 1.5 hours (range, 1.5–3.0 hours). Mean ± S.D. values for key pharmacokinetic parameters were 242 ± 123 ng/ml for Cmax, 894 ± 373 h ⋅ ng/ml for AUClast, and 908 ± 376 h ⋅ ng/ml for AUC∞. The apparent terminal elimination t1/2 was 14.5 ± 3.1 hours.

Treatment-emergent adverse events were reported by six subjects (38%) after pioglitazone alone and by two subjects (13%) following administration of pioglitazone after abiraterone acetate. All adverse events were mild in severity and resolved by the end of the study. Headache occurred in two subjects; all other adverse events were reported in one subject each. None was considered related to study treatment. There were no deaths, serious adverse events, or adverse events leading to discontinuation, or any clinically meaningful changes in other safety parameters.

Discussion

The results of the in vitro studies demonstrated that abiraterone acetate, abiraterone, and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, were inhibitors of CYP2C8 activity in human liver microsomes. Of these, abiraterone sulfate exhibited the most potent CYP2C8 inhibitory activity. Although not compared in the same assay, the data suggest that abiraterone sulfate is at least 10-fold more potent than abiraterone and its prodrug as a CYP2C8 inhibitor. Abiraterone acetate and abiraterone sulfate were predicted to have Ki values (inhibition constant = 0.5 × IC50) below 1 µM, which suggest high in vitro potency to cause in vivo drug interaction of at least two-fold (Obach et al., 2005). In a previous study, Cmax of abiraterone, abiraterone sulfate, and N-oxide abiraterone sulfate were reported to be approximately 0.37 µM, 25 µM, and 9.2 µM, respectively, after a single-dose administration of 1000 mg of abiraterone acetate to healthy volunteers (Bernard et al., 2015). The calculated R values (= 1 + [I] /Ki]) were greater than 1.1 for abiraterone and its metabolites, thus pointing toward the need for a clinical study to assess the interaction further. Although the concentrations of abiraterone acetate in blood were below the LLOQ of the assay in the vast majority of subjects (Acharya et al., 2012, 2013), the concentration in the liver is unknown, and therefore in vitro testing was conducted. The inhibition of CYP2C8 by abiraterone and its metabolites was reversible, as no evidence of time-dependent inhibition was seen. Although not performed as a fully quantitative investigation for OATP1B1 in vitro inhibition, the outcome was that pioglitazone rather than repaglinide was selected for the clinical study designed to ascertain if the CYP2C8 inhibitory activity seen in vitro has clinical significance.

In the clinical study, the pharmacokinetic analysis showed that oral coadministration of abiraterone acetate increased the Cmax for pioglitazone by 25% and exposure to pioglitazone as measured by AUClast and AUC∞ by 46% compared with administration of a single 15-mg dose of pioglitazone alone. Consistent with the increased exposure to pioglitazone, the GMR calculations showed that the Cmax and AUClast of M-III (keto derivative) and M-IV (hydroxyl derivative) were reduced by 10% to 13% when pioglitazone was administered with versus without abiraterone acetate. The small decreases in metabolite concentrations suggest that their formation was minimally affected by CYP2C8 inhibition caused by abiraterone. Although the enzymes involved in the metabolism of M-IV and M-III have not been identified, it has been reported that clearance of M-IV and M-III is inducible by rifampicin (Bernard et al., 2015; Jaakkola et al., 2006a), suggesting that CYP450s regulated by the pregnane X receptor gene may play a role (e.g., CYP3A4, CYP2C family). Considering the overall effect based on exposures to the total active compounds (sum of pioglitazone, M-III, and M-IV), it is probable that the net effect of abiraterone is a slight increase in the efficacy of pioglitazone by approximately 26% only. This magnitude of interaction is of little clinical relevance as it is comparable to that of ketoconazole, which is reported to increase the pioglitazone AUC by 34%, yet no dose adjustment or caution is necessary for pioglitazone when coadministered with ketoconazole (ACTOS; US prescribing information, 1999, Takeda Pharmaceuticals America, Inc., Deerfield, IL). Based on the extent of increase in pioglitazone exposure in this study, we conclude that administration of abiraterone acetate leads to mild or weak inhibition of CYP2C8, in accordance with regulatory guidelines from the European Medicines Agency (EMA) (European Medicines Agency Committee for Human Medicinal Products (CHMP) Guidelines on the investigation of drug interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.) and the US Department of Health and Human Services FDA Center for Drug Evaluation and Research (U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Drug interaction studies - study design: data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.). Moreover, the safety and tolerability assessment revealed no clinically relevant abnormalities when abiraterone acetate was coadministered with pioglitazone, consistent with prior experience with abiraterone acetate in other clinical studies in healthy adult males.

In this clinical interaction study, a standardized breakfast with medium fat was given 1 hour after the abiraterone acetate dose to obtain pharmacokinetic exposure to abiraterone similar to that observed previously in a multidose study conducted in cancer patients (COU-AA-006) (Tagawa et al., 2016). In that study, food intake followed the approved dosing and administration recommendation, with a meal allowed 2 hours before or 1 hour after abiraterone acetate dosing. The pharmacokinetic analysis showed an arithmetic mean Cmax of 207 ng/ml and an arithmetic mean AUC from time 0 to 24 hours of 965 h ⋅ ng/ml, which compare favorably with the Cmax of 242 ng/ml and AUC∞ of 908 ng ⋅ h/ml found in the present single-dose study.

Although the in vitro data suggest that abiraterone and its metabolites are potent CYP2C8 inhibitors, the clinical data are inconsistent with this finding. The extrapolation of in vitro data to predict in vivo drug-drug interactions can be affected by multiple biochemical and biophysical factors, including the biochemical assay environment and substrate-dependent effects (Wienkers and Heath, 2005). Abiraterone is highly bound (>99%) to plasma proteins (Zytiga prescribing information, 2015, Janssen Biotech, Inc., Horsham, PA); abiraterone sulfate and abiraterone sulfate N-oxide were also highly protein-bound in healthy subjects. The free fraction of these metabolites was <0.15% and 0.23%, respectively, and did not change when assessed in the presence of abiraterone (<0.15% and 0.22%, respectively) (data on file, Janssen Research & Development). Further, the fractions unbound in the CYP2C8 microsomal medium were 0.047, 0.42, and 0.901 μM for abiraterone, abiraterone sulfate, and abiraterone sulfate N-oxide, respectively, which resulted in IC50 values corrected for binding in the liver microsomes of 0.06–0.07 μM for abiraterone, 0.063–0.018 μM for abiraterone sulfate, and 5.3–4.87 μM for abiraterone sulfate N-oxide. Comparing these values with the unbound Cmax concentrations (0.0005 μM for abiraterone, 0.037 μM for abiraterone sulfate, and 0.055 μM for N-oxide abiraterone sulfate), only free plasma concentrations of abiraterone sulfate were in the order of magnitude of the IC50 (data on file, Janssen Research & Development). Applying the mechanistic static model (i.e., the EMA CHMP, 2012), using the unbound Cmax for abiraterone sulfate and a fraction metabolized of 0.78 for pioglitazone (Xiao et al., 2015) resulted in an AUC ratio of 2.7, which was still above the upper limit (1.7) of the measured increase in AUC ratio of pioglitazone, suggesting that the unbound Cmax overestimates the interaction in the equation. The static drug-drug interaction equation assumes that the maximal concentrations of abiraterone and its metabolites are constant over time, whereas in reality abiraterone sulfate (currently the major driver of the CYP2C8 drug-drug interaction) has a plasma half-life of 2.47 hours. This means that at 4 hours (tmax) after dosing, mild CYP2C8 inhibition occurs, but at 24 hours after dosing, in reality, no CYP2C8 inhibition of the sulfate metabolite is expected to occur.

It is unlikely that the use of amodiaquine for the in vitro studies and pioglitazone for the in vivo studies would account for the observed differences in potency of CYP2C8 inhibition as both have been reported to have comparable IC50 values in the presence of CYP2C8 inhibitors (Jaakkola et al., 2006c; Albassam et al., 2015). These results are not unique to abiraterone acetate. Similar findings were observed with the leukotriene antagonists montelukast and zafirlukast, which showed strong inhibition of CYP2C8 in vitro (IC50 = 0.51 µM and 1.0 µM, respectively) (Jaakkola et al., 2006c) but did not significantly affect the pharmacokinetics of pioglitazone or its metabolites in vivo (Jaakkola et al., 2006b). The results of our studies and those by Jaakkola et al. highlight the impact of relevant pharmacokinetic properties and plasma protein binding data on the outcome of in vitro–in vivo interaction predictions.

Abiraterone and its metabolites were found to inhibit the hepatic uptake transporter OATP1B1 in vitro. For abiraterone, the in vivo OATP1B1 inhibition potential was calculated according to the FDA and EMA drug-drug interaction guidance (EMA CHMP, 2012; FDA, 2012). Based on the calculated in vivo inhibition potential, any interaction for abiraterone is considered negligible as R was below 1.25 (FDA, 2012) or Ki was greater than 50 × unbound Cmax (EMA CHMP, 2012). The guidelines do not mention calculation of the in vivo interaction potential for metabolites; however, no clinical data are available to confirm the in vitro transporter-based interaction for the metabolites of abiraterone acetate.

In summary, abiraterone acetate and abiraterone and its major human metabolites exhibited considerable inhibition of CYP2C8 in human liver microsomes in vitro; however, administration of abiraterone acetate to healthy men had only weak effects on the pharmacokinetics of the CYP2C8 probe substrate pioglitazone. Clinicians should consider the therapeutic index of CYP2C8 substrates when administering abiraterone acetate and follow the approved product dosing recommendations.

Acknowledgments

The authors thank Thomas W. Griffin for critical review of the analyses and the manuscript. Writing assistance was provided by Shala Thomas and Lashon Pringle of PAREXEL and was funded by Janssen Global Services, LLC.

Authorship Contributions

Participated in research design: Chien, Gonzalez, Jiao, Sensenhauser, Snoeys, Wynant.

Conducted experiments: Gonzalez, Sensenhauser, Smit, Wynant.

Contributed new reagents or analytic tools: Stieltjens.

Performed data analysis: Bernard, Chien, Jiao, Sensenhauser, Smit.

Wrote or contributed to the writing of the manuscript: Monbaliu, Gonzalez, Bernard, Jiao, Sensenhauser, Snoeys, Stieltjes, Wynant, Smit, Chien.

Footnotes

    • Received April 6, 2016.
    • Accepted August 5, 2016.

  • This study was funded by Janssen Research & Development (formerly Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology).

  • dx.doi.org/10.1124/dmd.116.070672.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

Abbreviations

APR
apparent partition ratio
AUC
area under the curve
CI
confidence interval
DMSO
dimethylsulfoxide
GMR
geometric mean ratio
LC-MS/MS
liquid chromatography coupled with tandem mass spectrometry
LLOQ
lower limit of quantification
NRS
NADPH-regenerating system
OATP
organic anion transporting polypeptide

References

  1. ↵
    1. Acharya M,
    2. Bernard A,
    3. Gonzalez M,
    4. Jiao J,
    5. De Vries R, and
    6. Tran N
    (2012) Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 69:1583–1590.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Acharya M,
    2. Gonzalez M,
    3. Mannens G,
    4. De Vries R,
    5. Lopez C,
    6. Griffin T, and
    7. Tran N
    (2013) A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica 43:379–389.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Albassam AA,
    2. Mohamed ME, and
    3. Frye RF
    (2015) Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes. Xenobiotica 45:406–412.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Barrie SE,
    2. Potter GA,
    3. Goddard PM,
    4. Haynes BP,
    5. Dowsett M, and
    6. Jarman M
    (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267–273.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bernard A,
    2. Vaccaro N,
    3. Acharya M,
    4. Jiao J,
    5. Monbaliu J,
    6. De Vries R,
    7. Stieltjes H,
    8. Yu M,
    9. Tran N, and
    10. Chien C
    (2015) Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Clin Pharmacol Drug Dev 4:63–73.
    OpenUrlCrossRef
  6. ↵
    1. Daily EB and
    2. Aquilante CL
    (2009) Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10:1489–1510.
    OpenUrlCrossRefPubMed
  7. ↵
    1. et al. and
    2. COU-AA-301 Investigators
    1. de Bono JS,
    2. Logothetis CJ,
    3. Molina A,
    4. Fizazi K,
    5. North S,
    6. Chu L,
    7. Chi KN,
    8. Jones RJ,
    9. Goodman OB Jr., and
    10. Saad F
    et al. and COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Eckland DA and
    2. Danhof M
    (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108:234–242.
    OpenUrlCrossRef
  9. ↵
    1. Fizazi K,
    2. Scher HI,
    3. Molina A,
    4. Logothetis CJ,
    5. Chi KN,
    6. Jones RJ,
    7. Staffurth JN,
    8. North S,
    9. Vogelzang NJ,
    10. Saad F,
    11. et al., and
    12. COU-AA-301 Investigators
    (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gibbons JA,
    2. de Vries M,
    3. Krauwinkel W,
    4. Ohtsu Y,
    5. Noukens J,
    6. van der Walt JS,
    7. Mol R,
    8. Mordenti J, and
    9. Ouatas T
    (2015) Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet 54:1057–1069.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Guengerich FP
    (1988) Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48:2946–2954.
    OpenUrlFREE Full Text
  12. ↵
    1. Jaakkola T,
    2. Backman JT,
    3. Neuvonen M,
    4. Laitila J, and
    5. Neuvonen PJ
    (2006a) Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 61:70–78.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Jaakkola T,
    2. Backman JT,
    3. Neuvonen M,
    4. Niemi M, and
    5. Neuvonen PJ
    (2006b) Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 62:503–509.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Jaakkola T,
    2. Laitila J,
    3. Neuvonen PJ, and
    4. Backman JT
    (2006c) Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 99:44–51.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kalliokoski A,
    2. Backman JT,
    3. Neuvonen PJ, and
    4. Niemi M
    (2008) Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 18:937–942.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Karim A,
    2. Slater M,
    3. Bradford D,
    4. Schwartz L,
    5. Zhao Z,
    6. Cao C, and
    7. Laurent A
    (2007) Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin: effect of body weight, gender, and race on systemic exposures of each drug. J Clin Pharmacol 47:37–47.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kirchheiner J,
    2. Thomas S,
    3. Bauer S,
    4. Tomalik-Scharte D,
    5. Hering U,
    6. Doroshyenko O,
    7. Jetter A,
    8. Stehle S,
    9. Tsahuridu M,
    10. Meineke I,
    11. et al.
    (2006) Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 80:657–667.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lim HK,
    2. Duczak N Jr.,
    3. Brougham L,
    4. Elliot M,
    5. Patel K, and
    6. Chan K
    (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211–1219.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Marbury T,
    2. Lawitz E,
    3. Stonerock R,
    4. Gonzalez M,
    5. Jiao J,
    6. Breeding J,
    7. Haqq C,
    8. Verboven P,
    9. Stieltjes H,
    10. Yu M,
    11. et al.
    (2014) Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol 54:732–741.
    OpenUrlCrossRef
  20. ↵
    1. Massard C and
    2. Fizazi K
    (2011) Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876–3883.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Niemi M,
    2. Backman JT,
    3. Kajosaari LI,
    4. Leathart JB,
    5. Neuvonen M,
    6. Daly AK,
    7. Eichelbaum M,
    8. Kivistö KT, and
    9. Neuvonen PJ
    (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–478.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Niemi M,
    2. Leathart JB,
    3. Neuvonen M,
    4. Backman JT,
    5. Daly AK, and
    6. Neuvonen PJ
    (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380–387.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Obach RS,
    2. Walsky RL,
    3. Venkatakrishnan K,
    4. Houston JB, and
    5. Tremaine LM
    (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582–592.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Potter GA,
    2. Barrie SE,
    3. Jarman M, and
    4. Rowlands MG
    (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 38:2463–2471.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Rathkopf D and
    2. Scher HI
    (2013) Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 19:43–49.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ryan CJ,
    2. Smith MR,
    3. de Bono JS,
    4. Molina A,
    5. Logothetis CJ,
    6. de Souza P,
    7. Fizazi K,
    8. Mainwaring P,
    9. Piulats JM,
    10. Ng S,
    11. et al., and
    12. COU-AA-302 Investigators
    (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ryan CJ,
    2. Smith MR,
    3. Fizazi K,
    4. Saad F,
    5. Mulders PF,
    6. Sternberg CN,
    7. Miller K,
    8. Logothetis CJ,
    9. Shore ND,
    10. Small EJ,
    11. et al., and
    12. COU-AA-302 Investigators
    (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Ryan CJ and
    2. Tindall DJ
    (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651–3658.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Tagawa ST,
    2. Posadas EM,
    3. Bruce J,
    4. Lim EA,
    5. Petrylak DP,
    6. Peng W,
    7. Kheoh T,
    8. Maul S,
    9. Smit JW,
    10. Gonzalez MD,
    11. De PP,
    12. Tran N, and
    13. Nanus DM
    (2016) Phase 1b study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2016 Feb 3. pii: S0302-2838(16)00130-5. doi: 10.1016/j.eururo.2016.01.028. [Epub ahead of print]
  30. ↵
    1. VandenBrink BM,
    2. Foti RS,
    3. Rock DA,
    4. Wienkers LC, and
    5. Wahlstrom JL
    (2011) Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546–1554.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Wienkers LC and
    2. Heath TG
    (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Xiao Q,
    2. Tang L,
    3. Xu R,
    4. Qian W, and
    5. Yang J
    (2015) Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone. Biopharm Drug Dispos 36:603–612.
    OpenUrlCrossRef
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Drug-Drug Interaction Studies of Abiraterone and CYP2C8

Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit and Caly Chien
Drug Metabolism and Disposition October 1, 2016, 44 (10) 1682-1691; DOI: https://doi.org/10.1124/dmd.116.070672
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement